Altimmune, Inc.

Altimmune, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Altimmune, Inc. is not a good value stock. Altimmune, Inc. is not very popular among insiders. Altimmune, Inc. is a mediocre stock to choose.
Log in to see more information.
Altimmune, Inc. is a clinical stage company, which engages in the research and development of immuno...
ALT Fundamental Data by TradingView

News

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Simply Wall St We can readily understand why investors are attracted to unprofitable companies. For example, Altimmune ( NASDAQ:ALT...\n more…

Investors Purchase High Volume of Call Options on Altimmune (NASDAQ:ALT)
Investors Purchase High Volume of Call Options on Altimmune (NASDAQ:ALT)

Ticker Report Altimmune, Inc. (NASDAQ:ALT - Get Free Report) saw unusually large options trading activity on Tuesday. Stock investors acquired 12,235 call options on the company. This is an increase of 74...\n more…

Zurcher Kantonalbank Zurich Cantonalbank Purchases 9,635 Shares of Altimmune, Inc. (NASDAQ:ALT)
Zurcher Kantonalbank Zurich Cantonalbank Purchases 9,635 Shares of Altimmune, Inc. (NASDAQ:ALT)

Ticker Report Zurcher Kantonalbank Zurich Cantonalbank grew its position in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 190.7% during the second quarter, HoldingsChannel reports. The firm owned 14,688 shares of...\n more…

Altimmune spikes after presenting data for obesity drug
Altimmune spikes after presenting data for obesity drug

Seeking Alpha - Healthcare Altimmune spikes after presenting data for obesity drug...\n more…

CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Globe Newswire GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Altimmune, Inc. (Nasdaq:ALT), please note that the reduction of visceral adipose...\n more…

Altimmune call volume above normal and directionally bullish
Altimmune call volume above normal and directionally bullish

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…